CITIC Securities: Kangfang Bio (09926.HK) rated as "buy", innovative drug with excellent efficacy and broad market space.

Zhitong Finance APP learned that Citic Securities released a research report stating that in terms of pipeline research, Kangfang Biology (09926.HK) has multiple products in the research pipeline and indications that are about to be approved for marketing. At the same time, the existing research and development pipeline continues to expand and enrich, with a rich early research pipeline reserve and the ability for long-term sustainable development. In terms of product sales, the approval of Yida Fang for marketing will contribute to the company's product sales, and Kaitani's growth is stable, with the company's product sales revenue increasing year by year. Considering the excellent therapeutic effect and broad market space of the company's innovative drug products, a "buy" rating is given.